11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 549-555

  Oyama, Nobuyuki ^a,b   Miller, Tom R ^a,b   Dehdashti, Farrokh ^a,b   Siegel, Barry A ^a,b   Fischer, Keith C ^a   Michalski, Jeff M ^a,b   Kibel, Adam S ^b,c   Andriole, Gerald L ^b,c   Picus, Joel ^b,c   Welch, Michael J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11C acetate; PET; Prostate cancer

Indexed keywords

ACETIC ACID C 11; CARBON 11; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; TRACER; ACETIC ACID DERIVATIVE; CARBON; CARBON 11 ACETATE; CARBON-11 ACETATE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOPSY; BONE; BONE SCINTISCANNING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; RELIABILITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SERUM; SOFT TISSUE; TUMOR; ADENOCARCINOMA; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METASTASIS; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TUMOR RECURRENCE;

ACETATES; ADENOCARCINOMA; AGED; CARBON; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037639970     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jemal A, Thomas A, Murray T, Thun M Cancer statistics. 2002. CA Cancer J Clin 2002;52:23-47
2. Manyak M, Javin M The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer Semin Urol Oncol. 1998;16:145-152.
3. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am. 1998,25:591-601.
4. DelaPaz RL, Patronas NJ, Brooks RA, et al Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. Am J Neuroradiol 1983;4:826-829.
5. Rigo P, Paulus P, Caschten B, et al Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur J Nucl Med. 1996;23: 1641-1647.
6. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 1999;162:1322-1328.
7. Effert PJ, Bares R, Handt S, Wolff JM, Bull D, Jakes G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose J Urol. 1996;155:994-998.
8. 18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623-629.
9. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996; 199 751-756
10. Bender H, Schomburg A, Ruhlmann J, Biersack HJ. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res. 1997;17:1655-1660
11. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 1998;159.2041-2047.
12. Shreve PD. Carbon-11 acetate PET imaging of prostate cancer [abstract] J Nucl Med 1999;40(suppl).60P.
13. 11-acetate PET imaging of prostate cancer J Nucl Med 2002,43:181-186
14. Miller TR, Oyama N, Dehdashti F, et al. Imaging of prostate cancer recurrence with PET [abstract]. J Nucl Med 2001;42(suppl):120P.
15. Oyama N, Miller TR, Dehdashti F, et al Carbon-11-acetate PET imaging of recurrent prostate cancer [abstract]. J Urol 2002;167:173P.
16. Xu M, Luk W, Culter PD, Digby WM. Local threshold for segmented attenuation correction of PET imaging of the thorax. IEEE Trans Nucl Sci 1994;41 1532-1537
17. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer, data from the CaPSURE database. J Urol. 1998;160:1398-1404.
18. Partin AW, Pearson JD, Landts PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43 649-659
19. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994,152:1821-1825.
20. Murphy GP, Elgamal AA, Troychak MJ, Kenny GM Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 2000;42:315-317.
21. Shreve PD, Wahl RL Carbon-11-acetate PET imaging of renal cell carcinoma [abstract]. J Nucl Mud. 1999,40(suppl).257P
22. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380-1384
23. 11C-acetate-PET in patients with prostate cancer [abstract]. J Nucl Med 2001,42(suppl):287P
24. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117-122
25. Hara T, Kosaka N, Kishi H PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998,39:990-995
26. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-1419
27. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Canter Res. 2001;61 110-117.
28. 18F- fluoroethylcholine for cancer imaging with PET synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43 187-199.